Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead U.S. markets are only open for four trading days after taking a breather for the Independence Day holiday. It is a quiet...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...
On July 7, biotech ChemoCentryx (NASDAQ: CCXI) will be undergoing an event that could make or break its stock price. Its flagship drug candidate, avacopan, an oral molecule under investigation for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis,...
Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s dis...
Shares of ChemoCentryx (NASDAQ: CCXI) nosedived in May after an advisory committee for the U.s. Food and Drug Administration (FDA) released an underwhelming report on the efficacy of the company's most advanced drug, avacopan, which treats inflammatory and autoimmune diseases and ha...
SAN CARLOS, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June...
syahrir maulana/iStock via Getty Images Despite a loss of ~81.4% in the year so far, ChemoCentryx ([[CCXI]] +5.5%) is on course to record its sixth straight session of gains today. This week, the company announced a presentation at recently concluded ERA-EDTA (European Renal Association ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vertex Pharma (NASDAQ: VRTX ) stock is dropping on Friday following the release of results from a Phase 2 clinical trial. Source: Shutterstock That trial was testing the effectiveness of VX-864 . This is a po...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...